![]() Incidence of adverse events was balanced across the treatment groups. ![]() Medium and high-dose MF–IND–GLY also led to a greater improvement in trough FEV1 compared with high-dose FLU–SAL. Participants were randomised to receive one year of medium or high-dose mometasone–indacaterol–glycopyrronium (MF–IND–GLY) or mometasone–indacaterol (MF–IND) once daily, or twice daily fluticasone–salmeterol (FLU–SAL), a well-established ICS–LABA combination.Īt week 26, the researchers found that medium and high-dose MF–IND–GLY showed superior improvement in trough FEV1, the mean volume of air that can be forced out in one second after taking a deep breath immediately before the next dose of study drug, compared with the corresponding doses of MF–IND. The researchers included 3,092 patients aged 18–75 years with symptomatic asthma despite treatment with medium-dose or high-dose ICS–LABA, at least one exacerbation in the previous year, and a percentage of predicted FEV1 of less than 80%. Journal of Pharmaceutical Health Services ResearchĪ once-daily, single-inhaler combination of inhaled corticosteroid (ICS), long-acting Î☢-adrenoceptor agonist (LABA), and long-acting muscarinic receptor antagonist (LAMA) was superior to ICS–LABA in improving lung function in patients with inadequately controlled asthma, a study funded by Novartis has suggested.International Journal of Pharmacy Practice.Antimicrobial resistance and stewardship.Matera has participated as a lecturer and advisor in scientific meetings and courses under the sponsorship of Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi Farmaceutici, GlaxoSmithKline and Novartis, and has been a consultant to ABC Farmaceutici and Chiesi Farmaceutici. His department was funded by Almirall, Boehringer Ingelheim, Chiesi Farmaceutici, Novartis and Zambon. Calzetta has participated as an advisor in scientific meetings under the sponsorship of Boehringer Ingelheim and Novartis, received non-financial support from AstraZeneca, a research grant partially funded by Chiesi Farmaceutici, Boehringer Ingelheim, Novartis and Almirall, and is or has been a consultant to ABC Farmaceutici, Recipharm, Zambon, Verona Pharma and Ockham Biotech. Her department was funded by Almirall, Boehringer Ingelheim, Chiesi Farmaceutici, Novartis and Zambon. Rogliani participated as a lecturer and advisor in scientific meetings and courses under the sponsorship of Almirall, AstraZeneca, Biofutura, Boehringer Ingelheim, Chiesi Farmaceutici, GlaxoSmithKline, Menarini Group, Mundipharma and Novartis. His department was funded by Almirall, Boehringer Ingelheim, Novartis and Zambon. Cazzola has participated as a faculty member and advisor in scientific meetings and courses under the sponsorship of Almirall, AstraZeneca, Biofutura, Boehringer Ingelheim, Chiesi Farmaceutici, GlaxoSmithKline, Menarini Group, Lallemand, Mundipharma, Novartis, Pfizer, Recipharm, Verona Pharma and Zambon, and is or has been a consultant to ABC Farmaceutici, AstraZeneca, Chiesi Farmaceutici, Recipharm, Lallemand, Novartis, Ockham Biotech, Verona Pharma and Zambon. µL -1, could benefit from ICS/LABA/LAMA combination therapy.Ĭonflict of interest: M.This meta-analysis suggests that patients on single long-acting bronchodilator therapy or LABA/LAMA combination therapy, who still have exacerbations and have blood eosinophil counts ≥300 cells ![]() The risk of pneumonia did not differ between ICS/LABA/LAMA combination therapy and its comparators.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |